Infarktbedingter kardiogener Schock

Die Sterblichkeit des infarktbedingten kardiogenen Schockes (IKS) ist ca. 10-fach höher als bei einem Myokardinfarkt ohne hämodynamische Beeinträchtigung. Lediglich die schnellstmögliche Revaskularisation der infarktverursachenden Arterie konnte bislang die Sterblichkeit substanziell senken. Die deutsch-österreichische S3-Leitlinie „Infarktbedingter kardiogener Schock – Diagnose, Monitoring und Therapie“ [1] [2] integriert sowohl kardiologische Aspekte als auch intensivmedizinische Belange, um eine übergreifende Handlungsempfehlung für diese Patienten zu geben.

Schlüsselwörter

kardiogener Schock - Infarkt - Monitoring - Diagnose - Therapie

• Literatur

• 1 Werdan K, Boeken U, Briegel J. et al. Infarktbedingter kardiogener Schock – Diagnose, Monitoring und Therapie. Intensiv- und Notfallbehandlung 2021; 46: 1-110
• 2 AWMF. Infarkt-bedingter kardiogener Schock – Diagnose, Monitoring und Therapie. Registernr. 019–013. 28.02.2019 Accessed January 06, 2022 at: https://www.awmf.org/leitlinien/detail/ll/019–013.html
• 3 Scholz KH, Maier SKG, Maier LS. et al. Impact of treatment delay on mortality in ST-segment elevation myocardial infarction (STEMI) patients presenting with and without haemodynamic instability: results from the German prospective, multicentre FITT-STEMI trial. Eur Heart J 2018; 39: 1065-1074
• 4 Collet JP, Thiele H, Barbato E. et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021; 42: 1289-1367
• 5 Romero CM. Comparison of dopamine and norepinephrine in shock. N Engl J Med 2010; 362: 2328
• 6 Thiele H, Akin I, Sandri M. et al. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. N Engl J Med 2017; 377: 2419-2432
• 7 Bangalore S, Gupta N, Guo Y. et al. Outcomes with Invasive vs Conservative Management of Cardiogenic Shock Complicating Acute Myocardial Infarction. Am J Med 2015; 128: 601-608
• 8 Fincke R, Hochman JS, Lowe AM. et al. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol 2004; 44: 340-348
• 9 Lee J. Comparison of dopamine and norepinephrine in shock. N Engl J Med 2010; 362: 2328-2329
• 10 Prondzinsky R, Lemm H, Swyter M. et al. Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome. Crit Care Med 2010; 38: 152-160
• 11 Thiele H, Zeymer U, Neumann FJ. et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet 2013; 382: 1638-1645
• 12 Ibanez B, James S, Agewall S. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39: 119-177
• 13 van Diepen S, Hochman JS, Stebbins A. et al. Association Between Delays in Mechanical Ventilation Initiation and Mortality in Patients With Refractory Cardiogenic Shock. JAMA Cardiol 2020; 5: 965-967
• 14 Sleeper LA, Ramanathan K, Picard MH. et al. Functional status and quality of life after emergency revascularization for cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol 2005; 46: 266-273